Evidence map›Paper›PMID 31272506›Full record

ArticleRadiation oncology (London, England)2019

The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma.

Geumju Park, Si Yeol Song, Jin-Hee Ahn, Wan-Lim Kim, Jong-Seok Lee, Seong-Yun Jeong, Jae Won Park, Eun Kyung Choi, Wonsik Choi, In-Hye Jung

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Old and New Blood Markers in Human Colorectal Cancer.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Geumju ParkDepartment of Radiation Oncology, Inje University Haeundae Paik Hospital, Busan, South Korea.
Si Yeol SongDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. siyeol.song@gmail.com.ORCID http://orcid.org/0000-0003-0090-8345
Jin-Hee AhnDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Wan-Lim KimDepartment of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jong-Seok LeeDepartment of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Seong-Yun JeongAsan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jae Won ParkDepartment of Radiation Oncology, Yeungnam University Medical Center, Daegu, South Korea.
Eun Kyung ChoiDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Wonsik ChoiDepartment of Radiation Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea.
In-Hye JungDepartment of Radiation Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea.
Ulsan College · KRInje University Haeundae Paik Hospital · KRYeungnam University Medical Center · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2018-472Ministry of Education NRF-2017R1D1A1B03035167
6 · The paper itself

Abstract

backgroundSystemic inflammation plays a critical role in cancer progression and oncologic outcomes in cancer patients. We investigated whether preoperative inflammatory biomarkers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and neutrophil to lymphocyte ratio (NLR), could be surrogate biomarkers for predicting overall survival (OS) in soft tissue sarcoma (STS) patients treated with surgery and postoperative radiotherapy.

methodsA series of 99 patients who presented with localized extremity STS were retrospectively reviewed. The preoperative CRP levels, ESR, and NLR were evaluated for associations with OS, disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). Cutoff values for CRP, ESR, and NLR were derived from receiver-operating characteristic curve analysis.

resultsElevated CRP (> 0.14 mg/dL), ESR (> 15 mm/h), and NLR (> 1.95) levels were seen in 33, 44, and 45 patients, respectively. Of these three inflammatory biomarkers, elevated CRP and ESR were associated with a poorer OS (CRP: P = 0.050; ESR: P = 0.001), DFS (CRP: P = 0.023; ESR: P = 0.003), and DMFS (CRP: P = 0.015; ESR: P = 0.001). By multivariate analysis, an elevated ESR was found to be an independent prognostic factor for OS (HR 3.580, P = 0.025) and DMFS (HR 3.850, P = 0.036) after adjustment for other established prognostic factors.

conclusionsThe preoperative ESR level is a simple and useful surrogate biomarker for predicting survival outcomes in STS patients and might improve the identification of high-risk patients of tumor relapse in clinical practice.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorBlood SedimentationCombined Modality TherapyExtremitiesFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantRetrospective StudiesBiomarkers, TumorBiomarkerErythrocyte sedimentation rateESRPrognostic factorSarcomaSoft tissue sarcoma

Identifiers

PMID31272506
PMCPMC6610892
OpenAlexW2955642992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.